Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179718 | 0.94 | SLC2A1 (0.38) | SLC2A1ALDH1A1TSHROPRM1CHRNB2 | |
| SCHEMBL3179145 | 0.92 | SLC2A1 (0.41) | SLC2A1ALDH1A1TSHROPRM1LPAR3 | |
| SCHEMBL28455816 | 0.86 | CA2 (0.32) | OPRM1 | |
| SCHEMBL4036898 | 0.83 | NPC1 (0.41) | SLC2A1ALDH1A1TSHRCHRNB2CHRNA7 | |
| SCHEMBL28450378 | 0.82 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL28450375 | 0.82 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL3933992 | 0.81 | NPC1 (0.44) | SLC2A1ALDH1A1TSHRCHRNB2CHRNA7 | |
| SCHEMBL3946956 | 0.81 | NPC1 (0.44) | SLC2A1ALDH1A1TSHRCHRNB2CHRNA7 | |
| SCHEMBL3943932 | 0.79 | — | — | |
| SCHEMBL3943006 | 0.78 | NPC1 (0.36) | SLC2A1ALDH1A1TSHRLPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | claimed |
| CN-106309421-B | Pharmaceutical composition and cosmetic composition | 沃凯索法株式会社 | 2020-08-25 | — | — | CN | disclosed |
| US-8420853-B2 | Derivatives of cyclic compound and the use thereof | Wonkisopharm Co., Ltd (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | TYR, MC1R, PDE7A | SLC2A1 3555/4885ALDH1A1 2889/4885TSHR 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.